Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations

v3.7.0.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Revenue:    
Contract research revenue $ 0 $ 194,494
Costs and Expenses:    
Research and development 3,947,644 5,292,193
General and administrative 4,309,489 4,813,800
Total costs and expenses 8,257,133 10,105,993
Loss from operations (8,257,133) (9,911,499)
Sale of New Jersey net operating loss 674,901 756,472
Other income/(expense), net (16,505) 19,627
Net loss (7,598,737) (9,135,400)
Convertible preferred stock beneficial conversion feature accreted as a deemed dividend (4,393,809) 0
Net loss attributable to common shareholders $ (11,992,546) $ (9,135,400)
Net loss available for common shareholders per share - basic and diluted $ (0.21) $ (0.18)
Weighted average common shares outstanding:    
Basic and diluted (in shares) 57,654,830 51,481,002